Indeed, an interesting study by Sourbier et al. suggested that a combinatory treatment targeting both the metabolic rewiring and the activation of NRF2-dependent antioxidant signature is effective in FH-deficient RCC. The gene discussed is NFE2L2; the disease is renal cell carcinoma.